Emerging evidence and treatment paradigm of non-small cell lung cancer

Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unprecedented speed. The personalized treatment paradigm evolved every year. In this review, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Si-Yang Maggie, Zheng, Mei-Mei, Pan, Yi, Liu, Si-Yang, Li, Yangqiu, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108547/
https://www.ncbi.nlm.nih.gov/pubmed/37069698
http://dx.doi.org/10.1186/s13045-023-01436-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108547/
https://www.ncbi.nlm.nih.gov/pubmed/37069698
http://dx.doi.org/10.1186/s13045-023-01436-2

Ejemplares similares